# EDGAR Filing Document

**Accession Number:** 0001952094
**File Stem:** 0001193125-25-308375
**Filing Date:** 2025-12
**Character Count:** 23313
**Document Hash:** 88776d65bfb820f81ad196b442d11b0e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-308375.hdr.sgml**: 20251204

**ACCESSION NUMBER**: 0001193125-25-308375

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20251204

**DATE AS OF CHANGE**: 20251204

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TRINITY BIOTECH PLC
- **CENTRAL INDEX KEY:** 0000888721
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-44122
- **FILM NUMBER:** 251550996

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** IDA BUSINESS PARK
- **STREET 2:** BRAY
- **CITY:** WICKLOW
- **PROVINCE COUNTRY:** L2
- **BUSINESS PHONE:** 01135312955111

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** IDA BUSINESS PARK
- **STREET 2:** BRAY
- **CITY:** WICKLOW
- **PROVINCE COUNTRY:** L2
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MiCo IVD Holdings, LLC
- **CENTRAL INDEX KEY:** 0001952094

**ORGANIZATION NAME:**
- **EIN:** 881399456
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 85 ORCHARD ROAD
- **CITY:** SKILLMAN
- **STATE:** NJ
- **ZIP:** 08558
- **BUSINESS PHONE:** 8464705596

**MAIL ADDRESS:**
- **STREET 1:** 85 ORCHARD ROAD
- **CITY:** SKILLMAN
- **STATE:** NJ
- **ZIP:** 08558

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex1_b.pdf`

_No text found in this document._

**Attachment 2:** `ck0000000000-ex99_18.pdf`

_No text found in this document._

**Attachment 3:** `ck0000000000-ex99_19.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**Trinity Biotech plc**

*(Name of Issuer)*

**Class 'A' Ordinary Shares**

*(Title of Class of Securities)*

**896438504**

*(CUSIP Number)*

**Wonyong Park, President & CEO**<br>c/o MiCo IVD Holdings, LLC<br>85 Orchard Road<br>Skillman NJ 08558<br>512-650-6322

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/02/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **896438504** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**MiCo IVD Holdings, LLC** | Name of reporting person<br>**MiCo IVD Holdings, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**69450720.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**69450720.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**69450720.00** | Aggregate amount beneficially owned by each reporting person<br>**69450720.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.0%** | Percent of class represented by amount in Row (11)<br>**17.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Aggregate amount beneficially owned includes: (i) 44,759,380 Class 'A' ordinary shares ('Ordinary Shares') represented by 2,237,969 American Depository Shares ('ADS') owned by MiCo IVD Holdings, LLC ('MiCo IVD'), a wholly-owned subsidiary of AI n M net Ltd.; and (ii) 24,691,340 Ordinary Shares represented by 1,234,567 ADSs that would be issuable upon conversion of Issuer's 1.50 percent, seven-year, unsecured junior convertible note ('Convertible Note') with a conversion price of U.S. $16.20 per ADS (after giving effect to the ADS Ratio Change, as defined below) that is held by MiCo IVD. Each ADS reported on this Schedule 13D represents twenty (20) Ordinary Shares, which reflects an increase effected by the Company on February 23, 2024, of the number of Ordinary Shares represented by each ADS from four (4) Ordinary Shares (the 'ADS Ratio Change'). Percent of class represented by amount in Row (11) is based on 383,881,600 Class 'A' Ordinary Shares of the Issuer reported to be outstanding by the Issuer as of March 15, 2025 in the Issuer's final prospectus filed pursuant to Rule 424(b)(3) on March 31, 2025 and the 24,691,340 Ordinary Shares represented by ADSs issuable upon conversion of the Convertible Note.

| **CUSIP No.** | **896438504** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**AI n M net Ltd.** | Name of reporting person<br>**AI n M net Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**69450720.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**69450720.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**69450720.00** | Aggregate amount beneficially owned by each reporting person<br>**69450720.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.0%** | Percent of class represented by amount in Row (11)<br>**17.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Aggregate amount beneficially owned includes: (i) 44,759,380 Ordinary Shares represented by 2,237,969 ADSs owned by MiCo IVD; and (ii) 24,691,340 Ordinary Shares represented by 1,234,567 ADSs that would be issuable upon conversion of the Convertible Note. Each ADS reported on this Schedule 13D represents twenty (20) Ordinary Shares, which reflects the ADS Ratio Change. Percent of class represented by amount in Row (11) is based on 383,881,600 Class 'A' Ordinary Shares of the Issuer reported to be outstanding by the Issuer as of March 15, 2025 in the Issuer's final prospectus filed pursuant to Rule 424(b)(3) on March 31, 2025 and the 24,691,340 Ordinary Shares represented by ADSs issuable upon conversion of the Convertible Note.

| **CUSIP No.** | **896438504** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Wonyong Park** | Name of reporting person<br>**Wonyong Park** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M5** | Citizenship or place of organization<br>**M5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**69450720.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**69450720.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**69450720.00** | Aggregate amount beneficially owned by each reporting person<br>**69450720.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.0%** | Percent of class represented by amount in Row (11)<br>**17.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Aggregate amount beneficially owned includes: (i) 44,759,380 Ordinary Shares represented by 2,237,969 ADSs owned by MiCo IVD; and (ii) 24,691,340 Ordinary Shares represented by 1,234,567 ADSs that would be issuable upon conversion of the Convertible Note. Each ADS reported on this Schedule 13D represents twenty (20) Ordinary Shares, which reflects the ADS Ratio Change. Percent of class represented by amount in Row (11) is based on 383,881,600 Class 'A' Ordinary Shares of the Issuer reported to be outstanding by the Issuer as of March 15, 2025 in the Issuer's final prospectus filed pursuant to Rule 424(b)(3) on March 31, 2025 and the 24,691,340 Ordinary Shares represented by ADSs issuable upon conversion of the Convertible Note.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class 'A' Ordinary Shares

**(b) Name of Issuer:**
Trinity Biotech plc

**(c) Address of Issuer's Principal Executive Offices:**
IDA Business Park, Bray, County Wicklow, L2, A98 H5C8

The purpose of this Amendment No. 5 ("Amendment No. 5") to the joint statement on Schedule 13D with respect to the Class 'A' Ordinary Shares, par value U.S. $0.0001 per share (the "Ordinary Shares"), of Trinity Biotech, plc, a company organized under the laws of Ireland (the "Issuer"), filed by MiCo Co., Ltd. ("MiCo Parent") and MiCo IVD Holdings, LLC, a Delaware limited liability company ("MiCo IVD") on December 7, 2022 (such joint statement, as amended by Amendment No. 2 to the Schedule 13D filed by MiCo IVD, Mainstream Holdings, Ltd. ("Mainstream Holdings"), Mainstream New Growth No. 1 Private Equity Fund ("Mainstream NG"), New Main Equity Co., Ltd. ("New Main Equity") and Kim Chang-hee (together with Mainstream Holdings, Mainstream NG and New Main Equity, the "New Main Equity Filers") on January 2, 2024 and Amendment No. 3 to the Schedule 13D filed by MiCo IVD, DAYLI TRINITY HOLDINGS, Ltd. ("DAYLI Holdings"), DAYLI Fountainhead Project No. 3 Private Equity Fund ("DAYLI Fountainhead"), and DAYLI Partners, Inc. (together with DAYLI Holdings and DAYLI Fountainhead, the "DAYLI Filers") on December 19, 2024, and as amended herein, the "Schedule 13D"), filed jointly by the Reporting Persons (as defined below), is to report the change in the beneficial ownership of the Reporting Persons as a result of the execution of the 2025 MiCo IVD Purchase (as defined below) on December 2, 2025 and the execution of the Joint Filing Agreement by the Reporting Persons in connection with the 2025 MiCo IVD Purchase. Capitalized terms used but not defined herein have the respective meanings given to them in the Schedule 13D.

On January 2, 2024, MiCo Parent filed an Amendment No. 1 to the Schedule 13D ("Amendment No. 1") to report its sale of all of its equity interests in MiCo IVD to Mainstream Holdings and, on December 20, 2024, the New Main Equity Filers filed a Schedule 13D intended to serve as Amendment No. 4 to the Schedule 13D ("Amendment No. 4") to report the sale by Mainstream Holdings of all of its equity intetersts in MiCo IVD to DAYLI Holdings. Amendment No. 1 and Amendment No. 4 speak only of the beneficial ownership interests of MiCo Parent and the New Main Equity Filers, respectively, and the disclosures provided therein shall be disregarded in their entirety for the purposes of this Amendment No. 5, except that the exhibits included in response to Item 7 of each of Amendment No. 1 and Amendment No. 4 shall be incorporated herein by reference.

**Item 4. Purpose of Transaction**

Item 4 of Schedule 13D is hereby amended by deleting the final two paragraphs and replacing them with the following new paragraphs:

On December 2, 2025, DAYLI Holdings, the beneficial owner of 100% of the interests of MiCo IVD, entered into a Share Purchase Agreement with AI n M (the "2025 Share Purchase Agreement"), pursuant to which DAYLI Holdings agreed to sell to AI n M all of its equity interests in MiCo IVD for a total of 5,000,000,000 South Korean won (the "2025 MiCo IVD Purchase"). The 2025 MiCo IVD Purchase closed on December 2, 2025, following which time AI n M became the sole shareholder of MiCo IVD.

The foregoing description of the 2025 Share Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, an unofficial English translation copy of which is incorporated by reference as an exhibit to this Schedule 13D.

The applicable Reporting Persons made all acquisitions as described herein for investment purposes. As of the date of this Schedule 13D, the Reporting Persons may determine to dispose of all or a portion of MiCo IVD's holdings in the Issuer. Any disposition of these holdings may be made through private or public sales, including pursuant to the Resale Registration Statement, any trading plans that MiCo IVD might adopt pursuant to Rule 10b-5(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any hedging transactions. The Reporting Persons intend to review their investment in the Issuer on an ongoing basis and, in the course of their review, subject to the Conversion Limitation (as defined above and if applicable), may acquire additional equity interests, may retain or sell all or a portion of the equity interests of the Issuer held by the Reporting Persons, may distribute such equity interests held by the Reporting Persons to other entities and/or may take actions (including through their affiliates) with respect to their investment or the Issuer, including, without limitation, communicating with the Issuer's board of directors (the "Board"), members of management or other security holders of the Issuer, or other third parties (including, among others, creditors) from time to time, taking steps to implement a course of action with respect to the Issuer, including, without limitation, engaging advisors, including legal, financial, regulatory, technical and/or industry advisors, to assist in any review, and evaluating strategic alternatives regarding the Issuer and the ADS Investment. Such discussions and other actions may relate to, subject to the terms and conditions of the documents described herein to which the Reporting Persons are a party, various alternative courses of action, including, without limitation, those related to an extraordinary corporate transaction (including, but not limited to, an acquisition, merger, business combination, reorganization or liquidation) involving the Issuer or any of its subsidiaries; a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; material asset purchases; the formation of joint ventures with the Issuer or any of its subsidiaries or the entry into other material projects; changes in the present business, operations, strategy, future plans or prospects of the Issuer, financial or governance matters; changes to the Board (including board composition) or management of the Issuer; nominating individuals for consideration by the nomination committee of the Board for appointment to the Board; changes to the capitalization, ownership structure, dividend policy, business or corporate structure or governance documents of the Issuer; de-listing or de-registration of the Issuer's securities, or any action similar to those enumerated above. The Reporting Persons reserve the right to, and may in the future, discuss, meet with, and/or send correspondence to (a) the Issuer's management and/or Board, (b) other holders of securities of the Issuer, and/or (c) other third parties (including creditors) to discuss and/or formulate any plans or proposals regarding the Issuer or its securities. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. There can be no assurance, however, that any of the Reporting Persons will take any of the foregoing actions, and the Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or plans or proposals with respect thereto. This document (including the foregoing statements in this paragraph) is not intended to, and does not, constitute or form part of any offer, possible offer, invitation or the solicitation of an offer by the Reporting Persons to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to this document or otherwise.

The information set forth in or incorporated by reference in Item 3 of this Schedule 13D is incorporated by reference into this Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and restated in full as follows:

The aggregate number and percentage of the Ordinary Shares beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

As of the date hereof, the Reporting Persons may be deemed to beneficially own 69,450,720 Ordinary Shares consisting of: (i) 2,237,969 ADSs, which represent 44,759,380 Ordinary Shares and (ii) 1,234,567 ADSs representing 24,691,340 Ordinary Shares issuable upon conversion of the Convertible Note.  This represents an aggregate beneficial ownership of 17.0% of the Ordinary Shares, calculated on an as-converted basis assuming full conversion of the Convertible Note into ADSs.

The percentage of beneficial ownership is based upon 383,881,600 Ordinary Shares reported to be outstanding by the Issuer as of March 15, 2025 in the Issuer's final prospectus filed pursuant to Rule 424(b)(3) on March 31, 2025 and the 24,691,340 Ordinary Shares represented by ADSs issuable upon conversion of the Convertible Note held by MiCo IVD. AI n M may be deemed to be the beneficial owner of the Ordinary Shares beneficially owned by MiCo IVD through its ownership interests in MiCo IVD. Mr. Park may be deemed to be the beneficial owner of the Ordinary Shares beneficially owned by MiCo IVD through his position as manager, chief executive officer and president of MiCo IVD.

Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that AI n M or Mr. Park is the beneficial owner of Ordinary Shares referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and AI n M and Mr. Park expressly disclaim beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein.

**(b)**
Item 5(b) of the Schedule 13D is hereby amended and restated in full as follows:

The aggregate number and percentage of the Ordinary Shares beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

**(c)**
Item 5(c) of the Schedule 13D is hereby amended and restated in full as follows:
Except as set forth in this Schedule 13D, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any other person named in Item 2, has engaged in any transaction in Ordinary Shares during the past 60 days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** MiCo IVD Holdings, LLC

**Signature:** /s/ Wonyong Park

**Name/Title:** Wonyong Park/President and CEO

**Date:** 12/04/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** AI n M net Ltd.

**Signature:** /s/ Young S Hong

**Name/Title:** Young S Hong/Chief Executive Officer

**Date:** 12/04/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Wonyong Park

**Signature:** /s/ Wonyong Park

**Name/Title:** Wonyong Park

**Date:** 12/04/2025